Document Detail


Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease.
MedLine Citation:
PMID:  18158955     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A patient with extensive cutaneous chronic graft-versus-host disease (cGVHD) affecting 100% of the body surface, with painful ulcerations that involved 20% of it, was treated unsuccessfully during 9 months with steroids, cyclosporine-A (CSa), sirolimus, tacrolimus, mychophenolate mofetil (MMF), infliximab, and rituximab. Twenty-one months after the allograft the patient was started on alemtuzumab, 10 mg/day subcutaneously, for 6 consecutive days every 4 weeks. Seven months after starting the treatment, 100% of the ulcers had disappeared, as had the pain. To our knowledge, there are no reports of the use of alemtuzumab in the treatment of extensive, ulcerated, refractory cutaneous cGVHD. The data presented here suggest that this agent may be useful in some patients with refractory forms of cGVHD.
Authors:
Guillermo J Ruiz-Argüelles; Javier Gil-Beristain; Mario Magaña; Guillermo J Ruiz-Delgado
Related Documents :
6521615 - Steroid treatment lowers hepatic fibroplasia, as explored by serum aminoterminal procol...
9011365 - Topical steroid therapy in oral lichen planus: review of a novel delivery method in 24 ...
20172275 - Preliminary experience with alemtuzumab induction therapy combined with maintenance low...
18434855 - Long-term use of topical tacrolimus (fk506) in high-risk penetrating keratoplasty.
9848845 - The role of endoscopic third ventriculostomy in the management of shunt malfunction.
3369935 - Hemobilia. a disease in evolution.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2007-12-03
Journal Detail:
Title:  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation     Volume:  14     ISSN:  1523-6536     ISO Abbreviation:  Biol. Blood Marrow Transplant.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-26     Completed Date:  2008-01-22     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9600628     Medline TA:  Biol Blood Marrow Transplant     Country:  United States    
Other Details:
Languages:  eng     Pagination:  7-9     Citation Subset:  IM    
Affiliation:
Centro de Hematología y Medicina Interna de Puebla, Puebla, Mexico. gruiz1@clinicaruiz.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / therapeutic use*
Chronic Disease / drug therapy
Female
Graft vs Host Disease / drug therapy*,  pathology
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Leukemia, Myeloid, Acute / therapy
Skin Ulcer / drug therapy*,  pathology
Transplantation, Homologous / adverse effects
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 3A189DH42V/alemtuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Anesthesia condition for (18)F-FDG imaging of lung metastasis tumors using small animal PET.
Next Document:  Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.